Extendicare Inc.
TSX:EXE.TOMedical - Care Facilities
+$0.86 today
- Market cap
- $2.74B
- Beta
- 1.16
- P/E (TTM)
- 26.4
- EPS (TTM)
- $1.28
- Dividend yield
- 1.51%
Volume 0.86M
Average 0.34M
EXE.TO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Extendicare Inc.TSX: EXE.TO
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA grows, but more slowly than its trailing trend
Q2 FY2026 EBITDA of CA$62.68M rose 15.5% year over year, behind the +28.5% change in trailing-twelve-month EBITDA. Sequentially, it rose 18.7% from the prior quarter. Over 3 fiscal years it compounded at +52.7% a year.
Context
- EBITDA amounted to 10.6% of revenue in FY2025, unchanged from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of CA$288.17M (+64.1%) for the fiscal year ending Dec 2026, a step up from the +13.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- CA$62.68M+18.7% QoQ
- Last fiscal yearDec 2025
- CA$175.61M+13.1% YoY
- LTMJun 2026
- CA$213.41M+28.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +15.5% | +65.7% | +50.2 pp |
| 1 year | +13.1% | +64.1% | +51.0 pp |
| 3-year CAGR | +52.7% | +28.1% | -24.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
CAD · from the income statement
- Latest · FY2025
- 175.61M CAD
- Year-over-year change
- +13.1%
- 4-year CAGR
- +23.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 175.61M | +13.1% |
| FY2024 | 2024-12-31 | 155.27M | +57.4% |
| FY2023 | 2023-12-31 | 98.63M | +100.0% |
| FY2022 | 2022-12-31 | 49.33M | -34.2% |
| FY2021 | 2021-12-31 | 75M | — |
EBITDA vs competitors
How EXE.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +28.5% is the 4th highest of 7, against a peer median of +32.5%.
- EBITDA amounts to 10.8% of revenue for EXE.TO, versus a peer median of 21.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$219.35M CAD | +256.2% | +29.6% | 14.9% | |
| LTM Jun 2026 | CA$213.41M CAD | +28.5% | +52.7% | 10.8% | |
| LTM Sep 2026 | CA$202.95M CAD | +39.8% | +16.4% | 18.3% | |
| LTM Mar 2026 | $75.52M USD | -3.6% | +5.1% | 24.7% | |
| LTM Mar 2026 | $47.83M USD | +356.7% | — | 30.0% | |
| LTM Mar 2026 | CA$30.12M CAD | +25.2% | — | 8.0% | |
| LTM Feb 2026 | -$1.34B USD | -106.7% | — | 156.2% | |
| Peer median (excluding EXE.TO) | — | +32.5% | +16.4% | 21.5% | |
Competitors are the stored peer set for EXE.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.17B | 1.22B | 1.3B | 1.47B | 1.66B |
| Cost of Revenue | 1.05B | 1.14B | 1.14B | 1.3B | 1.46B |
| Gross Profit | 115.61M | 76.83M | 167.62M | 168M | 199.59M |
| Gross Margin | 9.9% | 6.3% | 12.8% | 11.5% | 12.0% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 69.79M | 51.08M | 55.84M | 1.2B | 1.36B |
| Operating Expenses | 52.43M | 50.78M | 55.84M | 56.94M | 61.22M |
| Depreciation & Amortization | 38.57M | 32.12M | 32.23M | 33.34M | 37.25M |
| EBITDA | 75M | 49.33M | 98.63M | 155.27M | 175.61M |
| EBITDA Margin | 6.4% | 4.0% | 7.6% | 10.6% | 10.6% |
| Operating Income | 49.71M | 20.99M | 62.96M | 111.21M | 138.37M |
| Operating Margin | 4.3% | 1.7% | 4.8% | 7.6% | 8.3% |
| Interest Income | 1.87M | 5.02M | 6.19M | 7.04M | 5.73M |
| Interest Expense | 22.45M | 21.7M | 21.6M | 21.1M | 19.23M |
| Other Income / Expenses | (35.72M) | (25.48M) | (18.16M) | (11.35M) | (8.26M) |
| Income Before Tax | 13.99M | (4.5M) | 44.8M | 99.86M | 130.1M |
| Pre-Tax Margin | 1.2% | -0.4% | 3.4% | 6.8% | 7.8% |
| Income Tax Expense | 6.48M | 15K | 10.82M | 24.65M | 33.45M |
| Net Income | 11.5M | 69.55M | 33.98M | 75.21M | 96.66M |
| Net Margin | 1.0% | 5.7% | 2.6% | 5.1% | 5.8% |
| EPS (Basic) | 0.13 | 0.85 | 0.40 | 0.97 | 1.13 |
| EPS (Diluted) | 0.13 | 0.85 | 0.40 | 0.86 | 1.11 |
| Weighted Avg Shares | 89.99M | 89.01M | 84.99M | 84.22M | 85.4M |
| Weighted Avg Shares (Diluted) | 100.9M | 89.01M | 84.99M | 95.36M | 86.84M |
Extendicare Inc.
TSX:EXE.TO
Intrinsic Alpha fair value
Locked
Current Price
$28.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.